CMPS Rallies 17.91% as Technical Signals Turn Bearish

1. Market Snapshot

Headline Takeaway: Compass Pathways (CMPS.O) is currently showing a 17.91% price rise, but technical signals are bearish and analyst expectations are pessimistic.

Though the stock has recently gained ground, the technical outlook is weak, and there's a mismatch between price action and analyst sentiment.

2. News Highlights

Recent news includes developments in pharmaceuticals and regulatory changes, though none directly impact Compass Pathways. Notable highlights:

• Regeneron Pharmaceuticals reported 27% reduction in COPD exacerbations in a Phase 3 trial for itepekimab. This highlights ongoing progress in drug development, which could affect investor sentiment toward Compass Pathways' own pipeline.
• China's factory activity contracted slightly in May, but at a slower pace, signaling tentative signs of economic recovery. This could indirectly affect Compass Pathways if global demand for mental health therapies rebounds.

3. Analyst Views & Fundamentals

Average Rating Score: 4.33 (simple mean), Weighted Rating Score: 0.00. Analyst ratings are inconsistent and broadly underperform the market, with no bullish consensus. The historical win rate for analysts is 0%, indicating poor reliability.

The price trend is upward, but analyst expectations are weighted pessimistically, leading to a mismatch in direction.

Key Fundamental Factor Values and Model Scores:

• Revenue-MV: -27.29% (model score: 3)
• Total operating revenue (YoY growth rate %): 78.33% (model score: 2)
• Inventory turnover ratio: 47.77% (model score: 1)
• Quick ratio: 2.20% (model score: 1)
• Profit-MV: 0.44% (model score: 2)
• PB-ROE: 99.02% (model score: 3)
• Interest coverage ratio (EBIT / Interest expense) (%): 15.65% (model score: 2)
• Cost of sales ratio (%): 70.41% (model score: 2)
• Asset-MV: -49.43% (model score: 3)
• Net profit / Total profit (%): 100.13% (model score: 0)

4. Money-Flow Trends

Big-money and retail flows show a mixed picture:

• Small investors: 50.59% inflow; trend is positive.
• Medium investors: 50.46% inflow; trend is positive.
• Large and extra-large investors: 47.89% and 48.96% inflow respectively; trends are negative.
• Overall inflow: 48.95% (score: 7.73, internal diagnostic score (0-10)).

Block flows are down overall (48.72% inflow), suggesting institutional hesitation.

5. Key Technical Signals

Technical indicators are bearish, with the internal diagnostic score at 3.35—a clear suggestion to avoid the stock for now.

Key Indicators and Their Internal Diagnostic Scores:

• Long Lower Shadow: 4.0
• Long Upper Shadow: 2.28
• MACD Golden Cross: 6.13
• Hanging Man: 1.0

Recent Chart Patterns (Last 5 Days):

• 2026-02-24: Long Lower Shadow
• 2026-02-23: Long Lower Shadow
• 2026-02-19: Long Lower Shadow, Hanging Man
• 2026-02-18: Long Upper Shadow, Long Lower Shadow
• 2026-02-17: Long Lower Shadow, Long Upper Shadow, MACD Golden Cross

Key insights: Technical momentum is unclear and volatile, and bearish signals outnumber bullish ones, with 2 bearish vs 0 bullish indicators active.

6. Conclusion

Actionable Takeaway: Consider waiting for a pull-back before entering a position in Compass Pathways. Despite the current 17.91% price rise, the technical trend is weak, and the analyst consensus is negative. Investors may want to watch for improved momentum or better alignment between technical and fundamental factors before committing capital.